John Jui-Jen Lee - Feb 25, 2022 Form 4 Insider Report for Decibel Therapeutics, Inc. (DBTX)

Role
Chief Development Officer
Signature
/s/ Elisabeth Leiderman, Attorney-in-Fact
Stock symbol
DBTX
Transactions as of
Feb 25, 2022
Transactions value $
$0
Form type
4
Date filed
2/28/2022, 03:37 PM
Next filing
Jan 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DBTX Stock Options (right to buy) Award $0 +52.5K $0.00 52.5K Feb 25, 2022 Common Stock 52.5K $3.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026.